摘要
目的评价贝那普利与黄葵联合治疗慢性肾小球肾炎患者的临床治疗效果以及用药安全性。方法86例慢性肾小球肾炎患者作为研究对象,依据治疗方式不同分为实验组和对照组,每组43例。对照组患者采用贝那普利进行治疗,实验组患者采用贝那普利联合黄葵进行治疗。对比两组患者临床疗效、不良反应发生情况及治疗前后肾功能指标、血压水平。结果实验组患者治疗总有效率为95.35%,明显高于对照组的81.40%,差异具有统计学意义(P<0.05)。实验组患者不良反应发生率6.98%低于对照组的23.26%,差异具有统计学意义(P<0.05)。治疗后,实验组患者尿素氮为(7.15±0.48)mmol/L、血肌酐为(121.63±5.34)μmol/L、24 h尿蛋白定量为(0.84±0.40)g/24 h,均低于对照组的(9.40±0.61)mmol/L、(136.82±6.07)μmol/L、(1.04±0.47)g/24 h,差异具有统计学意义(t=19.0081、12.3207、2.1250,P=0.0000、0.0000、0.0365<0.05)。治疗后,实验组患者收缩压为(122.93±8.16)mm Hg(1 mm Hg=0.133 kPa)、舒张压为(70.42±5.10)mm Hg,均低于对照组的(131.07±8.52)、(73.21±4.66)mm Hg,差异具有统计学意义(t=4.5246、2.6483,P=0.0000、0.0097<0.05)。结论慢性肾小球肾炎患者采用贝那普利与黄葵进行联合治疗,患者的临床疗效更加显著,各项临床指标得到明显改善,且用药后不良反应发生几率较低,具有较高的安全性。
Objective To evaluate the clinical effect and drug safety of benazepril combined with abelmoschus moschatus in chronic glomerulonephritis.Methods A total of 86 patients with chronic glomerulonephritis as the research subjects were divided into experimental group and control group according to different treatment methods,with 43 cases in each group.Patients in the control group were treated with benazepril,and patients in the experimental group were treated with benazepril and abelmoschus moschatus.Both groups were compared in terms of clinical efficacy,occurrence of adverse reactions,renal function indicators and blood pressure before and after treatment.Results The total effective rate of treatment in the experimental group was 95.35%,which was significantly higher than 81.40%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 6.98%in the experimental group was lower than 81.40%in the control group,and the difference was statistically significant(P<0.05).After treatment,the urea nitrogen(7.15±0.48)mmol/L,blood creatinine(121.63±5.34)μmol/L,and 24-h urinary protein quantification(0.84±0.40)g/24 h of the experimental group,which were lower than(9.40±0.61)mmol/L,(136.82±6.07)μmol/L and(1.04±0.47)g/24 h of the control group,and the difference was statistically significant(t=19.0081,12.3207,2.1250;P=0.0000,0.0000,0.0365<0.05).After treatment,the systolic blood pressure(122.93±8.16)mm Hg(1 mm Hg=0.133 kPa),and diastolic blood pressure(70.42±5.10)mm Hg of the experimental group were lower than(131.07±8.52)and(73.21±4.66)mm Hg of the control group,and the difference was statistically significant(t=4.5246,2.6483;P=0.0000,0.0097<0.05).Conclusion Combination of benazepril and abelmoschus moschatus has significant clinical efficacy on patients with chronic glomerulonephritis,and it can significantly improve the clinical indicators,with lower incidence of adverse reactions after medication and high safety.
作者
石静
SHI Jing(Lianshan District People’s Hospital,Huludao 125001,China)
出处
《中国现代药物应用》
2021年第21期31-33,共3页
Chinese Journal of Modern Drug Application
关键词
慢性肾小球肾炎
贝那普利
黄葵
安全性
Chronic glomerulonephritis
Benazepril
Abelmoschus moschatus
Safety
